148 related articles for article (PubMed ID: 16730924)
1. Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependence.
Elkashef A; Fudala PJ; Gorgon L; Li SH; Kahn R; Chiang N; Vocci F; Collins J; Jones K; Boardman K; Sather M
Drug Alcohol Depend; 2006 Dec; 85(3):191-7. PubMed ID: 16730924
[TBL] [Abstract][Full Text] [Related]
2. Selegiline transdermal system in the prevention of relapse of major depressive disorder: a 52-week, double-blind, placebo-substitution, parallel-group clinical trial.
Amsterdam JD; Bodkin JA
J Clin Psychopharmacol; 2006 Dec; 26(6):579-86. PubMed ID: 17110814
[TBL] [Abstract][Full Text] [Related]
3. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.
Amsterdam JD
J Clin Psychiatry; 2003 Feb; 64(2):208-14. PubMed ID: 12633131
[TBL] [Abstract][Full Text] [Related]
4. Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.
Feiger AD; Rickels K; Rynn MA; Zimbroff DL; Robinson DS
J Clin Psychiatry; 2006 Sep; 67(9):1354-61. PubMed ID: 17017821
[TBL] [Abstract][Full Text] [Related]
5. Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS).
Jang S; Jung S; Pae C; Kimberly BP; Craig Nelson J; Patkar AA
J Affect Disord; 2013 Dec; 151(3):854-9. PubMed ID: 24021959
[TBL] [Abstract][Full Text] [Related]
6. Transdermal selegiline and intravenous cocaine: safety and interactions.
Houtsmuller EJ; Notes LD; Newton T; van Sluis N; Chiang N; Elkashef A; Bigelow GE
Psychopharmacology (Berl); 2004 Feb; 172(1):31-40. PubMed ID: 14605792
[TBL] [Abstract][Full Text] [Related]
7. Selegiline transdermal system: current awareness and promise.
Pae CU; Lim HK; Han C; Neena A; Lee C; Patkar AA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1153-63. PubMed ID: 17614182
[TBL] [Abstract][Full Text] [Related]
8. Treatment effects of selegiline transdermal system on symptoms of major depressive disorder: a meta-analysis of short-term, placebo-controlled, efficacy trials.
Robinson DS; Gilmor ML; Yang Y; Moonsammy G; Azzaro AJ; Oren DA; Campbell BJ
Psychopharmacol Bull; 2007; 40(3):15-28. PubMed ID: 18007565
[TBL] [Abstract][Full Text] [Related]
9. Selegiline transdermal system Somerset.
Mahmood I
Curr Opin Investig Drugs; 2002 Aug; 3(8):1230-3. PubMed ID: 12211421
[TBL] [Abstract][Full Text] [Related]
10. Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.
Thase ME
J Clin Psychiatry; 2006 Apr; 67(4):671-2. PubMed ID: 16669733
[No Abstract] [Full Text] [Related]
11. A comprehensive assessment of the safety of intravenous methamphetamine administration during treatment with selegiline.
Newton TF; De La Garza R; Fong T; Chiang N; Holmes TH; Bloch DA; Anderson A; Elkashef A
Pharmacol Biochem Behav; 2005 Dec; 82(4):704-11. PubMed ID: 16413604
[TBL] [Abstract][Full Text] [Related]
12. Transdermal selegiline in patients receiving electroconvulsive therapy.
Horn PJ; Reti I; Jayaram G
Psychosomatics; 2010; 51(2):176-8. PubMed ID: 20332294
[TBL] [Abstract][Full Text] [Related]
13. A phase 1 trial of pharmacologic interactions between transdermal selegiline and a 4-hour cocaine infusion.
Harris DS; Everhart T; Jacob P; Lin E; Mendelson JE; Jones RT
BMC Clin Pharmacol; 2009 Aug; 9():13. PubMed ID: 19646280
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
[TBL] [Abstract][Full Text] [Related]
15. Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study.
Sacktor N; Schifitto G; McDermott MP; Marder K; McArthur JC; Kieburtz K
Neurology; 2000 Jan; 54(1):233-5. PubMed ID: 10636157
[TBL] [Abstract][Full Text] [Related]
16. Transdermal selegiline.
Patkar AA; Pae CU; Zarzar M
Drugs Today (Barc); 2007 Jun; 43(6):361-77. PubMed ID: 17612708
[TBL] [Abstract][Full Text] [Related]
17. Treatment-resistant depression: response to low-dose transdermal but not oral selegiline.
Morgan PT
J Clin Psychopharmacol; 2007 Jun; 27(3):313-4. PubMed ID: 17502787
[No Abstract] [Full Text] [Related]
18. Selegiline transdermal system: in the treatment of major depressive disorder.
Frampton JE; Plosker GL
Drugs; 2007; 67(2):257-65; discussion 266-7. PubMed ID: 17284087
[TBL] [Abstract][Full Text] [Related]
19. The selegiline transdermal system in major depressive disorder: a systematic review of safety and tolerability.
Robinson DS; Amsterdam JD
J Affect Disord; 2008 Jan; 105(1-3):15-23. PubMed ID: 17568687
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
